Subscribe
shutterstock_121153783_sahara_prince
Sahara Prince / Shutterstock.com
5 July 2021Big PharmaAlex Baldwin

Five minutes with… Dmitry Karshtedt

Genus claims—or patent claims covering a family of related compounds—are commonplace in life sciences patent law. But following a rising trend of invalidity rulings, the future of the claim seems bleak.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
Five minutes with… Jacqueline Mulryne
26 November 2020   The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.
Biotechnology
Five minutes with… Penny Gilbert
9 March 2021   The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

article
Five minutes with… Jacqueline Mulryne
26 November 2020   The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.
Biotechnology
Five minutes with… Penny Gilbert
9 March 2021   The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.

More on this story

article
Five minutes with… Jacqueline Mulryne
26 November 2020   The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.
Biotechnology
Five minutes with… Penny Gilbert
9 March 2021   The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York